Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 31;14(15):3746.
doi: 10.3390/cancers14153746.

Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis

Evgenii Shumilov  1 , Lena Aperdannier  2 , Nicole Schmidt  2 , Christoph Szuszies  2 , Albrecht Neesse  3 , Petra Hoffknecht  4 , Cyrus Khandanpour  1   5 , Jan-Henrik Mikesch  1 , Matthias Stelljes  1 , Göran Ramin Boeckel  6   7 , Phil-Robin Tepasse  6 , Lea Reitnauer  1 , Raphael Koch  2 , Justin Hasenkamp  2 , Ulrike Bacher  8 , Simone Scheithauer  9 , Lorenz Trümper  2 , Norbert Schmitz  1 , Gerald Wulf  2 , Andrea Kerkhoff  1 , Georg Lenz  1 , Carolin Krekeler  1 , Annalen Bleckmann  1
Affiliations

Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis

Evgenii Shumilov et al. Cancers (Basel). .

Abstract

COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analyzed SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated and non-vaccinated patients from three German cancer centers. Overall, 133 patients with SARS-CoV-2 were enrolled in pre- and post-vaccine eras: 84 non-vaccinated and 49 vaccinated, respectively. A mild course of COVID-19 was documented more frequently in vaccinated patients (49% vs. 29%), while the frequency of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%, p = 0.023). Particularly, patients with hematologic neoplasms benefited from vaccination in this context (p = 0.031). Admissions to intermediate- and intensive-care units and the necessity of non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients, respectively. The median length of admission was 11 days for non-vaccinated and 5 days for vaccinated patients (p = 0.002). COVID-19 mortality was reduced by 83% in vaccinated patients (p = 0.046). Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively (p = 0.002). Although this study does not have enough power to perform multivariate analyses to account for confounders, it provides data on COVID-19 in non-vaccinated and vaccinated cancer patients and illustrates the potential benefits of COVID-19 vaccines for these patients.

Keywords: COVID-19; COVID-19 vaccination; SARS-CoV-2; cancer patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Clinical, diagnostic, and treatment aspects of COVID-19 course among non- and vaccinated cancer patients of the study.
Figure 2
Figure 2
Severity of SARS-CoV-2 infection in non- and vaccinated cancer patients of the study.
Figure 3
Figure 3
(A) Overall survival among non- and vaccinated patients; (B) cancer mortality among non- and vaccinated patients; (C) COVID-19 mortality among non- and vaccinated patients; (D) treatment delay, development of progressive disease, and median time from SARS-CoV-2 infection to therapy restart among non- and vaccinated patients of this study.
See this image and copyright information in PMC

References

    1. Saini K.S., Tagliamento M., Lambertini M., McNally R., Romano M., Leone M., Curigliano G., de Azambuja E. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur. J. Cancer. 2020;139:43–50. doi: 10.1016/j.ejca.2020.08.011. - DOI - PMC - PubMed
    1. Lee L.Y.W., Cazier J.-B., Angelis V., Arnold R., Bisht V., Campton N.A., Chackathayil J., Cheng V.W.T., Curley H.M., Fittall M.W., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet. 2020;395:1919–1926. doi: 10.1016/S0140-6736(20)31173-9. - DOI - PMC - PubMed
    1. Pinato D.J., Zambelli A., Aguilar-Company J., Bower M., Sng C.C.T., Salazar R., Bertuzzi A., Brunet J., Mesia R., Seguí E., et al. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discov. 2020;10:1465–1474. doi: 10.1158/2159-8290.CD-20-0773. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. El Sahly H.M., Baden L.R., Essink B., Doblecki-Lewis S., Martin J.M., Anderson E.J., Campbell T.B., Clark J., Jackson L.A., Fichtenbaum C.J., et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N. Engl. J. Med. 2021;385:1774–1785. doi: 10.1056/NEJMoa2113017. - DOI - PMC - PubMed